

RPG LIFE SCIENCES LIMITED

25, M.I.D.C Land, Thane - Belapur Road, Navi Mumbai 400 705, India

Phones : 6795 5400 / 5555 / 5399 / 5398, Fax : 2767 2646 / 2763 1052



April 27, 2012

The Manager
Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G. Block
Bandra- Kurla Complex, Bandra (E)
Mumbai 400 051

Scrip Symbol : RPGLIFE

Dear Sir,

Sub: Audited financial results and recommendation of dividend
for the year ended March 31, 2012.

This is to inform that the Board of Directors at its meeting held on April 27, 2012 has -

- 1) approved the enclosed audited financial results for the year ended March 31, 2012.
- 2) recommended an equity dividend of Rs.0.80 per share (10%) for the year ended March 31, 2012, subject to the approval of the members at the ensuing Annual General Meeting.

Kindly take the above on your record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head - Legal & Company Secretary


Encl: As above

RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.

PART I					(Rs. in lakhs)
STATEMENT OF STANDALONE AUDITED RESULTS FOR THE YEAR ENDED 31st MARCH, 2012					
Particulars	3 months ended 31.3.2012	3 months ended 31.12.2011	3 months ended 31.3.2011	Year ended 31.3.2012	Year ended 31.3.2011
	Unaudited	Unaudited	Unaudited	Audited	Audited
1. Income from Operations					
(a) Net Sales/Income from Operations (Net of Excise Duty)	4,123	4,630	5,213	18,923	18,355
(b) Other Operating Income	97	77	138	359	328
Total Income from Operations	4,220	4,707	5,351	19,282	18,683
2. Expenses					
(a) Cost of Materials Consumed	931	955	1,170	4,465	4,500
(b) Purchases of Stock-in-Trade	354	298	441	1,195	1,429
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	194	114	(195)	(140)	(957)
(d) Employee Benefits Expense	1,224	1,268	1,055	4,999	4,024
(e) Depreciation and Amortisation Expense	260	258	247	1,022	952
(f) Other Expenses	1,782	1,607	1,910	6,948	6,432
Total Expenses	4,745	4,500	4,628	18,489	16,380
3. Profit/(Loss) from Operations before Other Income and Finance Costs	(525)	207	723	793	2,303
4. Other Income	12	(16)	30	69	72
5. Profit/(Loss) from Ordinary Activities before Finance Costs	(513)	191	753	862	2,375
6. Finance Costs	130	162	153	688	628
7. Profit/(Loss) from Ordinary Activities before Tax	(643)	29	600	174	1,747
8. Tax Expense/(Credit) (including Deferred Tax)	(74)	(17)	168	89	476
9. Net Profit/(Loss) for the period	(569)	46	432	85	1,271
10. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323
11. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)				6,091	6,160
12. Earnings/(Loss) per Share (of Rs. 8 each) (not annualised):					
(a) Basic	(3.44)	0.28	2.61	0.51	8.04
(b) Diluted	(3.44)	0.28	2.61	0.51	7.69

PART II					
Select Information for the Quarter and Year ended 31st March, 2012					
Particulars	3 months ended 31.3.2012	3 months ended 31.12.2011	3 months ended 31.3.2011	Year ended 31.3.2012	Year ended 31.3.2011
A PARTICULARS OF SHAREHOLDING					
1. Public Shareholding					
- Number of Shares	7,754,293	7,770,593	8,066,291	7,754,293	8,066,291
- Percentage of Shareholding	46.90	46.99	48.78	46.90	48.78
2. Promoters and Promoter Group Shareholding					
(a) Pledged/Encumbered					
- Number of Shares	-	-	-	-	-
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-	-
- Percentage of Shares (as a % of the total Share Capital of the company)	-	-	-	-	-
(b) Non-Encumbered					
- Number of Shares	8,780,948	8,764,648	8,468,950	8,780,948	8,468,950
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total Share Capital of the company)	53.10	53.01	51.22	53.10	51.22



Particulars	3 months ended 31.3.2012
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	8
Disposed of during the quarter	8
Remaining unsolved during the quarter	-

Notes:**1. Standalone Statement of Assets and Liabilities**

Particulars	(Rs. in lakhs)	
	As at 31.3.2012	As at 31.3.2011
A EQUITY AND LIABILITIES		
1. Shareholders' Funds		
(a) Share Capital	1,323	1,323
(b) Reserves and Surplus	6,091	6,160
Sub-total - Shareholders' Funds	7,414	7,483
2. Non-Current Liabilities		
(a) Long-term Borrowings	2,067	2,480
(b) Deferred Tax Liabilities (Net)	682	596
(c) Other Long-term Liabilities	722	706
(d) Long-term Provisions	118	76
Sub-total - Non-Current Liabilities	3,589	3,858
3. Current Liabilities		
(a) Short-term Borrowings	2,439	2,034
(b) Trade Payables	3,323	3,985
(c) Other Current Liabilities	1,288	1,108
(d) Short-term Provisions	237	468
Sub-total - Current Liabilities	7,287	7,595
TOTAL - EQUITY AND LIABILITIES	18,290	18,936
B ASSETS		
1. Non-Current Assets		
(a) Fixed Assets	10,997	11,275
(b) Long-term Loans and Advances	147	260
(c) Other Non-Current Assets	67	59
Sub-total - Non-Current Assets	11,211	11,594
2. Current Assets		
(a) Inventories	2,890	2,631
(b) Trade Receivables	3,009	3,835
(c) Cash and Bank Balances	56	48
(d) Short-term Loans and Advances	1,115	828
Sub-total - Current Assets	7,079	7,342
TOTAL - ASSETS	18,290	18,936

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 27th April, 2012.
- The figures for the quarter ended 31st March, 2012 are the balancing figures between the audited financial results for the year ended 31st March, 2012 and the published unaudited financial results for the nine months ended 31st December, 2011.
- The company is exclusively engaged in pharmaceuticals segment.
- The company continues to invest strongly in building of brands to gain market share.
- Towards the end of December 2011, the company received a communication from the Ministry of Social and Family Affairs, Health and Consumer Protection, Hamburg, Germany not granting EU GMP certification for the company's API facility at Navi Mumbai, Maharashtra post their inspection, citing certain deficiencies. Consequently, some of the orders were cancelled for the quarter ended 31st March, 2012, adversely affecting the business of the company. The company has promptly initiated remedial measures towards gaining re-certification, which are expected to be completed in the next 3 quarters.



7. The Board of Directors has recommended dividend of Rs. 0.80 per share (10%) for the year ended 31st March, 2012. This will absorb Rs. 151 lakhs including Dividend Distribution Tax.
8. Figures for the prior periods have been regrouped where necessary.



For RPG Life Sciences Limited

Ajit Singh Chouhan
Managing Director
Mumbai, 27th April, 2012